Clinical trial
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon…
NCT00083720 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00083720 |
|---|---|
| Title | Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy |
| Official title | A Phase II Multicenter Study of Erbitux (Cetuximab) in Patients With Refractory, EGFR-Negative Metastatic Colorectal Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms, Metastases, Neoplasm |
| Intervention type | Biological |
| Interventions | cetuximab |
| Enrollment | 87 |
| Start date | Oct 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Jun 2, 2004 |
| Last update posted | May 25, 2011 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: